Eli Lilly raised its full-year 2026 sales outlook after third-quarter revenue and earnings beat analyst estimates, driven by strong demand for Zepbound and Mounjaro. The company now expects 2026 revenue of $91 billion to $92 billion, up from its previous guidance of $85 billion to $87 billion. Its shares rose about 7% on Thursday, according to the report.
Mounjaro's worldwide revenue rose 65% to $10.72 billion in the quarter, including about $5 billion in U.S. sales. Analysts had expected $10.10 billion in worldwide sales, according to StreetAccount. Zepbound posted $5.35 billion in revenue, up 49% from a year earlier, above the $5.09 billion analysts expected.
Sales of Foundayo, Lilly's GLP-1 obesity pill launched in the U.S. in April, reached $184 million. That fell short of analyst forecasts of around $229 million. Lilly CFO Lucas Montarces said U.S. prescriptions for Foundayo doubled from the previous quarter, and that about 4 in 10 patients starting an oral obesity medicine choose it.
Lilly said it holds 63% of the U.S. obesity and diabetes drug market, compared with Novo's 36.6%, according to its earnings presentation. CEO Dave Ricks told CNBC that he estimates 3% to 10% of eligible patients in the U.S. access obesity care, and said the "room for expansion here of this market is dramatic."
The company reported net income of $6.45 billion, or $7.22 per share, including $4.57 per share in charges tied to deals made in the quarter. Excluding one-time items, Lilly posted earnings of $7.48 per share.